Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10609537 | 0.89 | MAPK1 (0.61) | MAPK1ESR1ESR2AURKAAURKB | |
| SCHEMBL10610835 | 0.85 | SMN1; SMN2 (0.51) | MAPK1ESR1ESR2HPGDALDH1A1 | |
| SCHEMBL16097168 | 0.84 | MCL1 (0.46) | ESR1ESR2HPGDALDH1A1PTGES | |
| SCHEMBL12201040 | 0.83 | ESR1 (0.53) | ESR1ESR2ALDH1A1ALOX5HIF1A | |
| SCHEMBL6534510 | 0.83 | MAPK1 (0.55) | MAPK1ESR1ESR2AURKAAURKB | |
| SCHEMBL1256551 | 0.83 | ACHE (0.61) | HPGDCYP2C9DHODHSMN1; SMN2L3MBTL1 | |
| SCHEMBL10612958 | 0.83 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL16098232 | 0.81 | MAPK1 (0.54) | MAPK1ESR1ESR2AURKAAURKB | |
| SCHEMBL20696076 | 0.81 | ACHE (0.59) | HPGDCYP2C9DHODHSMN1; SMN2L3MBTL1 | |
| Methane SCHEMBL10433561 | 0.81 | ACHE (0.59) | HPGDCYP2C9DHODHSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023110936-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | NETHERLANDS TRANSLATIONAL RESEARCH CENTER HOLDING B.V (NL) | 2023-06-22 | — | — | WO | disclosed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA (FR) | 2019-01-15 | — | — | US | disclosed |
| CN-105102442-B | Quinoline as anticarcinogen | 基因科学医药公司 | 2018-11-09 | — | — | CN | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| EP-2976333-B1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA SAS (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2016-09-29 | — | — | US | disclosed |
| EP-2976333-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | Genoscience Pharma SAS (FR) | 2016-01-27 | — | — | EP | disclosed |
| CN-105102442-A | Quinolines derivatives as novel anticancer agents | GENOSCIENCE PHARMA | 2015-11-25 | — | — | CN | disclosed |
| WO-2014147611-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147611-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | GENOSCIENCE PHARMA (FR) | 2014-09-25 | — | — | WO | disclosed |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011060112-A1 | DEUTERATED TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060112-A1 | DEUTERATED TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-4728647-A | Amides derived from quinoline, and anxiolytic compositions containing them | RHONE-POULENC SANTE (FR) | 1988-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179770-B2 | Quinolines derivatives as novel anticancer agents | NQO2, MKI67, NQO1 | MAPK1 1963/4885ESR1 3660/4885ESR2 3752/4885 |
| US-20160280653-A1 | QUINOLINES DERIVATIVES AS NOVEL ANTICANCER AGENTS | NQO2, MKI67, NQO1 | MAPK1 1963/4885ESR1 3660/4885ESR2 3752/4885 |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | IGF1R, INSR, IRS1 | MAPK1 41/4885ESR1 792/4885ESR2 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.